Skip to main content
. 2023 Oct 25;38(1):198–201. doi: 10.1038/s41375-023-02072-y

Fig. 2. ROC curves for relapse prediction in AML patients after allogeneic HSCT according to the MRCH burden (black), NPM1 MRD burden (red), and the bone marrow CD34 chimerism (blue) as continuous variables, measured in morphologic remission.

Fig. 2

A relapse within 28 days after measurement, (B) relapse within day 56 days after measurement, and (C) relapse within 84 days after measurement.